Merck Advances Immunology Pipeline with Evobrutinib (Bruton’s Tyrosine Kinase Inhibitor)

  • Phase IIa signal finding trial of evobrutinib in rheumatoid arthritis patients progresses to Phase IIb
  • Patient enrollment completed significantly ahead of schedule in multiple sclerosis trial
  • One of the broadest clinical programs of a BTK inhibitor in multiple autoimmune disorders underway with three Phase II clinical trials

DARMSTADT, Germany I September 12, 2017 I Merck, a leading science and technology company, today announced that it is continuing to advance its Immunology pipeline.

Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor (BTKi) discovered by Merck, is now in Phase IIb studies across multiple immunological indications: rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE).

“Our strategic aim in Immunology is to deliver best-in-disease treatment options to patients with high unmet medical needs,” says Luciano Rossetti, Head of Global R&D for the biopharma business of Merck. “Our broad clinical trial program for evobrutinib in multiple immune-mediated disorders underscores our belief in its potential for patients living with chronic diseases.”

In RA, Merck recently initiated a Phase IIb study after results from a small Phase IIa signal-generating study (n=65) met the pre-defined criteria for progressing to a dose finding study. The purpose of this signal study was to characterize the role of evobrutinib in patients with a broad range of disease activity. The study did not reach the statistical criteria across all patients enrolled, however, there was a clear positive outcome in the pre-specified patient population conventionally studied across RA pivotal trials, which is the population to be enrolled in the Phase IIb dose-finding study. Full results of the Phase IIa trial will be presented at a future scientific meeting.

In multiple sclerosis, the Phase II clinical trial is evaluating the safety and effectiveness of evobrutinib in patients with relapsing remitting MS. Patients have been placed into one of five groups, receiving evobrutinib at one of three different dose levels, placebo or dimethyl fumarate, for 24 weeks. After 24 weeks, the patients on placebo will be given evobrutinib. Patient enrollment is now complete, with Merck achieving its goal of enrolling 250 patients across 55 sites six months ahead of schedule.

Merck’s Phase II systemic lupus erythematosus study is on schedule to read out in Q4 2019.

Merck is evaluating strategic partnerships and financing for evobrutinib in order to realize the full potential of the program.

Merck is also investigating another proprietary BTK inhibitor in oncology: M7583 is currently being evaluated in a Phase I clinical trial for hematological malignancies.

SOURCE: Merck KGaA

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top